| Nov 15 |
Genelux GAAP EPS of -$0.19 beats by $0.01
|
| Nov 15 |
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
|
| Nov 14 |
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
|
| Nov 6 |
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
|
| Oct 31 |
Genelux: H2 2025 PRROC Data Is A Major Inflection Point
|
| Oct 31 |
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well
|
| Oct 29 |
Genelux started at buy by Guggenheim ahead of Olvi-vec data
|
| Oct 25 |
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp
|
| Oct 23 |
Genelux doses first subject in Phase II trial of NSCLC treatment
|
| Oct 22 |
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
|
